Protagenic Therapeutics
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. over the previous period. Total operating expenses were $4,526,974.
Profit Margin
| 2014 | 0 | -1.07M | |
|---|---|---|---|
| 2015 | 0 | -476K | |
| 2016 | 0 | -2.27M | |
| 2017 | 0 | -2.25M | |
| 2018 | 0 | -2.55M | |
| 2019 | 0 | -1.76M | |
| 2020 | 0 | -2.79M | |
| 2021 | 0 | -4.98M | |
| 2022 | 0 | -3.60M | |
| 2023 | 0 | -5.00M |
PTIX Income Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||
Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cost of revenue | 28.21K | 30 | 0 | 286 | 339 | 347 | 148 | 534 | 0 | 0 |
Gross profit | -28.21K | -30 | 0 | -286 | -339 | -347 | -148 | -534 | 0 | 0 |
Operating exp. | ||||||||||
Research and development | 3.31M | 1.58M | 1.13M | 699.79K | 807.94K | 881.18K | 717.45K | 417.86K | 464 | 42K |
Selling and marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 115.82K | 0 | 0 |
Total operating expenses | 4.52M | 3.55M | 4.14M | 2.55M | 2.08M | 2.31M | 2.36M | 1.82M | 491K | 975K |
Operating income | -4.52M | -3.55M | -4.14M | -2.55M | -2.08M | -2.31M | -2.36M | -2.23M | -491K | -975K |
Other income (expenses), net | -473.52K | 2.28K | -382.52K | 2.87K | 335.21K | -246.19K | 105.68K | -440.23K | 1.61K | -57.9K |
Income before tax | -5.00M | -3.55M | -4.52M | -2.54M | -1.75M | -2.55M | -2.25M | -2.27M | -501K | -924K |
Income tax expense | 0 | 46.05K | 463.70K | 246.17K | 15.88K | 486.80K | -105.68K | 440.23K | -33K | 101K |
Net income | -5.00M | -3.60M | -4.98M | -2.79M | -1.76M | -2.55M | -2.25M | -2.27M | -476K | -1.07M |
Earnings per share | ||||||||||
Basic EPS | -1.15 | -0.83 | -1.35 | -1.08 | -0.69 | -1 | -0.88 | -1.72 | -73.23 | -166.86 |
Diluted EPS | -1.15 | -0.83 | -1.35 | -1.08 | -0.69 | -1 | -0.88 | -1.72 | -73.23 | -166 |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |